HNSA — Hansa Biopharma AB Cashflow Statement
0.000.00%
Last trade - 00:00- SEK2.99bn
- SEK3.23bn
- SEK222.27m
Annual cashflow statement for Hansa Biopharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -548 | -611 | -832 | -807 | -529 |
| Depreciation | |||||
| Non-Cash Items | 56.4 | 71.4 | 18 | 153 | 13.7 |
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.12 | 25 | 38.3 | -48.5 | -33.7 |
| Change in Accounts Receivable | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -481 | -503 | -756 | -675 | -549 |
| Capital Expenditures | -2.4 | -3.33 | -0.284 | -0.116 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | 233 | 0 | — | — |
| Sale/Maturity of Investment | |||||
| Cash from Investing Activities | -2.4 | 229 | -0.284 | -0.116 | 0 |
| Financing Cash Flow Items | — | — | — | — | -9.53 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -4.86 | 1,118 | -7.54 | 347 | 848 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -488 | 845 | -764 | -327 | 296 |